opdualag
bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanoma - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.
sotyktu
bristol-myers squibb pharma eeig - deucravacitinib - psorajiżi - immunosoppressanti - treatment of moderate-to-severe plaque psoriasis in adults.